Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid save search
SINTX Technologies announces a fabric technology shown to inactivate upon contact SARS-CoV-2, the virus causing the COVID-19 pandemic
Published: 2021-03-09 (Crawled : 14:12) - globenewswire.com
SINT | $0.039 4.56% 4.36% 430M
|
Health Technology
|
| O: 20.99%
H: 31.51%
C: 31.05%
covid sars-cov-2
SINTX Technologies and Iwatani Group Announce Agreement to Develop Antipathogenic Surfaces to Help Prevent Spread of the Common Flu, COVID-19, and Other Viral Diseases
Published: 2020-11-13 (Crawled : 10:13) - globenewswire.com
SINT | $0.039 4.56% 4.36% 430M
|
Health Technology
|
| O: 2.38%
H: 3.49%
C: 2.33%
covid disease
O2TODAY ANNOUNCES AGREEMENT TO DEVELOP ANTIMICROBIAL FACE MASKS WITH SINTX TECHNOLOGIES INC. TO HELP PREVENT SPREAD OF COVID-19 AND OTHER VIRAL DISEASES
Published: 2020-08-04 (Crawled : 10:13) - globenewswire.com
SINT | $0.039 4.56% 4.36% 430M
|
Health Technology
|
| O: 26.76%
H: 22.22%
C: 20.74%
covid disease
O2TODAY and SINTX Technologies Enter Commercialization Agreement to Fight COVID-19
Published: 2021-02-25 (Crawled : 14:04) - globenewswire.com
SINT | $0.039 4.56% 4.36% 430M
|
Health Technology
|
| O: 8.33%
H: 19.43%
C: -2.02%
covid commercialization covid-19
Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients
Published: 2021-08-03 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.75%
H: 5.97%
C: 4.59%
VNDA | $4.97 -5.15% -5.43% 3.9M
|
Health Technology
|
| O: -1.6%
H: 1.86%
C: 1.68%
covid enroll
Qilian International Holding Group Limited Donates Pharmaceutical Products Gan Di Xin® Worth RMB500,000 and Other Materials to Help Fight Local COVID-19 Epidemic
Published: 2021-11-01 (Crawled : 12:00) - prnewswire.com
QLI | $0.8 -10.23% -11.4% 29K
|
Manufacturing
|
| O: -1.88%
H: 2.05%
C: 1.37%
covid xin
PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome
Published: 2022-01-07 (Crawled : 14:00) - biospace.com/
PXMD | $0.7784 -2.69% -2.76% 710K
|
Health Technology
| Email alert
Add to watchlist
pax-101 covid-19 phase 1b covid phase 1 syndros phase 2b
$903 Million Worldwide Facial Treatment Industry to 2027 - Impact of COVID-19 on the Market
Published: 2021-04-09 (Crawled : 17:00) - prnewswire.com
CUTR | $2.3 -3.36% -3.48% 1.1M
|
Health Technology
|
| O: -0.29%
H: 0.6%
C: -0.16%
covid treatment covid-19
$60.3 Billion Aesthetic Medicine Industry to 2027 - Impact of COVID-19 on the Market
Published: 2021-06-04 (Crawled : 15:15) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.58%
H: 0.34%
C: -0.62%
SIEN | $0.174 0.69% 3.4M
|
Health Technology
|
| O: 0.57%
H: 1.42%
C: 0.0%
CUTR | $2.3 -3.36% -3.48% 1.1M
|
Health Technology
|
| O: -0.05%
H: 3.56%
C: 3.18%
covid aesthetic covid-19
XpresSpa Group and United Airlines Announce the Opening of an XpresCheck™ COVID-19 Testing Facility at Houston George Bush Intercontinental Airport
Published: 2021-03-08 (Crawled : 14:00) - globenewswire.com
UAL | $51.41 5.48% 5.19% 37M
|
Transportation
|
| O: 1.64%
H: 5.81%
C: 5.28%
covid test
XpresCheck™ Opens COVID-19 Testing Facility at San Francisco International Airport
Published: 2021-04-21 (Crawled : 14:15) - globenewswire.com
UAL | $51.41 5.48% 5.19% 37M
|
Transportation
|
| O: -0.83%
H: 4.03%
C: 3.97%
covid test covid-19
Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment
Published: 2021-09-02 (Crawled : 14:00) - biospace.com/
RGC | $6.13 29.39% 22.72% 11K
|
Manufacturing
|
| O: 5.28%
H: 9.58%
C: -8.44%
covid treatment bioscience
INOVIO’s COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
Published: 2021-04-15 (Crawled : 12:00) - inovio.com
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: 11.09%
H: 5.6%
C: -8.25%
covid vaccine ino-4800 response
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
Published: 2020-12-03 (Crawled : 15:00) - biospace.com/
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: 2.29%
H: 9.28%
C: 2.25%
covid vaccine ino-4800
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: -0.91%
H: 0.92%
C: 0.3%
covid china vaccine trial phase 2 ino-4800
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
Published: 2021-01-04 (Crawled : 16:00) - biospace.com/
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: 2.26%
H: 8.51%
C: 7.51%
covid china vaccine partnership commercialization ino-4800
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
Published: 2021-05-10 (Crawled : 12:00) - prnewswire.com
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: 2.04%
H: 3.0%
C: -4.58%
covid phase 2 positive vaccine trial ino-4800
INOVIO’s Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies
Published: 2021-05-12 (Crawled : 12:00) - inovio.com
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: 1.39%
H: 0.3%
C: -4.26%
covid vaccine ino-4800 preclinical pre-clinical
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
Published: 2021-09-22 (Crawled : 12:15) - inovio.com
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: 0.25%
H: 0.76%
C: -1.14%
covid vaccine phase 3 trial authorized ino-4800
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.